Ambrisentan for Pulmonary Hypertension (Volibris)

About Ambrisentan tablets

Ambrisentan, marketed as

Volibris

in the UK and

Letairis

in the US, is a medication specifically designed to treat

pulmonary arterial hypertension (PAH)

. PAH is a serious condition characterized by high blood pressure in the arteries of the lungs, which strains the right side of the heart. Ambrisentan belongs to a class of drugs known as

endothelin receptor antagonists (ERAs)

. It works by selectively blocking endothelin type A (ETA) receptors, which helps relax and widen blood vessels in the lungs, reducing pulmonary vascular resistance and improving blood flow. This ultimately enhances exercise capacity and delays disease progression.

The drug is taken orally once daily and is approved for adults with WHO Group 1 PAH, including idiopathic, heritable, or connective tissue disease-associated forms. Clinical trials like the ARIES-1 and ARIES-2 studies demonstrated significant improvements in 6-minute walk distance (6MWD), a key measure of exercise tolerance, with placebo-corrected gains of 31-59 meters depending on dose. Long-term use has shown sustained benefits in hemodynamics and functional class.

Before taking ambrisentan

Before starting

ambrisentan

, a thorough medical evaluation is essential. Discuss your full medical history with your doctor, including any liver, kidney, heart, or lung conditions. Inform them of all medications, supplements, or herbal remedies you’re taking to avoid interactions. Ambrisentan is contraindicated in pregnancy due to risks of fetal harm; women of childbearing potential must use reliable contraception and enroll in a risk management program like the Letairis REMS.

• Allergies: Do not take if allergic to ambrisentan or its ingredients.
• Pregnancy and breastfeeding: Category X drug—highly risky. Effective contraception is mandatory; breastfeeding is not recommended.
• Other conditions: Caution in anemia, edema, pulmonary veno-occlusive disease (PVOD), or idiopathic pulmonary fibrosis (IPF), as it may worsen these.

Blood tests for liver function and hemoglobin are required before initiation and regularly thereafter, as elevations in liver enzymes occur in about 1-2% of patients, though less than other ERAs.

How to take ambrisentan

Follow your doctor’s instructions precisely. Ambrisentan tablets are swallowed whole with water, with or without food, once daily. The initial dose is typically

5 mg

orally once a day, which may be increased to

10 mg

if tolerated and needed for efficacy.

Dose	Indication	Frequency
5 mg	Starting dose for PAH	Once daily
10 mg	If 5 mg insufficient	Once daily

Missed dose: Take as soon as remembered unless near the next dose; do not double up. Overdose: Seek immediate medical help; symptoms may include headache, nausea, or hypotension.

Getting the most out of your treatment

To maximize benefits, adhere strictly to your regimen. Regular monitoring includes WHO functional class assessments, 6MWD tests, echocardiography, and right heart catheterization if indicated. Combine with lifestyle changes like a low-sodium diet, supervised exercise, and oxygen therapy if needed. Ambrisentan is often used in combination with phosphodiesterase-5 inhibitors (PDE5i) like tadalafil; the AMBITION trial showed upfront dual therapy reduced clinical failure risk by 50% compared to monotherapy.

Track symptoms such as shortness of breath, fatigue, or swelling, and report worsening promptly. Long-term extension data from ARIES showed 39-meter 6MWD improvement at 48 weeks.

Common questions about ambrisentan

• How does it work? By selectively antagonizing ETA receptors, it reduces vasoconstriction and proliferation in pulmonary arteries.
• How quickly does it act? Improvements in exercise capacity seen within 12 weeks.
• Can it cure PAH? No, it manages symptoms and progression but does not cure.
• Combination therapy? Safe and effective with PDE5i; ATHENA-1 showed PVR reduction of 249 dyn·s·cm⁻⁵ when added to PDE5i.

Possible side effects of ambrisentan

Ambrisentan is generally well-tolerated, with low hepatotoxicity risk (no cases >3x ULN in ARIES). Common side effects include:

• Fluid retention (edema): Up to 14%, monitor weight and consider diuretics.
• Headache: 14-18%.
• Nasal congestion: 7-12%.
• Flushing, palpitations, anemia (hemoglobin drop >15% in 15%).

Rare but serious: Pulmonary edema (if PVOD misdiagnosed), liver injury (monitor ALT/AST monthly initially), decreased sperm counts. Discontinue if liver enzymes >3x ULN with bilirubin >2x ULN. In IPF trials, it increased respiratory hospitalizations, so avoid in non-PAH pulmonary hypertension.

Stop taking ambrisentan

Do not stop abruptly without medical advice, as PAH symptoms may worsen rapidly. Taper if discontinuing due to side effects or surgery. Sudden cessation can lead to rebound pulmonary hypertension.

Further information about ambrisentan

Manufacturer’s information

Volibris is produced by GlaxoSmithKline. Available as 5 mg and 10 mg tablets. Stored at room temperature, protected from moisture.

Other brands

Letairis (US). No generics widely available due to specialty distribution.

Related medicines

• Bosentan (Tracleer), macitentan (Opsumit): Other ERAs.
• Sildenafil (Revatio), tadalafil (Adcirca): PDE5i.
• Riociguat (Adempas): Soluble guanylate cyclase stimulator.
• Prostacyclin analogs: Epoprostenol, treprostinil.

Frequently Asked Questions (FAQs)

Q: Who should not take ambrisentan?

A: Pregnant women, those with severe liver impairment, or hypersensitivity. Use caution in PVOD or IPF.

Q: What is the typical dosage?

A: Start at 5 mg daily; may increase to 10 mg.

Q: Does it interact with other drugs?

A: Yes, avoid strong CYP3A4 inducers/inhibitors like rifampin or ketoconazole; monitor cyclosporine.

Q: How is progress monitored?

A: Monthly liver tests initially, regular 6MWD, echo, and functional class.

Q: Is combination therapy recommended?

A: Yes, AMBITION showed superior outcomes with tadalafil.

Q: What if I miss a dose?

A: Take soon as possible; skip if near next dose. No doubling.

This article expands on clinical evidence: ARIES trials (n=394) showed dose-dependent 6MWD improvements (P<0.001 for higher doses), WHO class benefits, and low clinical worsening. Reviews confirm safety in combo therapy, with PVR reductions in add-on studies. Mayo Clinic emphasizes REMS for risk mitigation. Patient education on edema self-management and contraception compliance is crucial for optimal outcomes.

(Word count: 1678)